Combined Paclitaxel and Gemcitabine for Lung Cancer
Author Information
Author(s): Douillard J Y, Lerouge D, Monnier A, Bennouna J, Haller A M, Sun X S, Assouline D, Grau B, Rivière A
Primary Institution: Centre René Gauducheau
Hypothesis
The study evaluates the efficacy and toxicity of combined paclitaxel and gemcitabine in patients with metastatic non-small cell lung cancer.
Conclusion
Combined paclitaxel and gemcitabine is an effective and well-tolerated treatment for advanced non-small cell lung cancer.
Supporting Evidence
- 2 patients achieved a complete response and 15 achieved a partial response.
- The overall response rate was 36.2%.
- The median survival time was 51 weeks.
- Grade 3/4 neutropenia occurred in 15.2% of treatment courses.
- Peripheral neurotoxicity developed in 47.2% of patients.
Takeaway
This study tested a combination of two cancer drugs on patients with lung cancer and found it helped many of them feel better.
Methodology
Patients received gemcitabine and paclitaxel in a specific schedule, and their responses were monitored.
Potential Biases
Potential biases may arise from the non-randomized design.
Limitations
The study was limited to a small sample size and was not randomized.
Participant Demographics
Patients had a median age of 53 years, with most having stage IV disease and adenocarcinoma histology.
Statistical Information
Confidence Interval
95% CI: 22.4–49.9%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website